1. Home
  2. BRSP vs IMMX Comparison

BRSP vs IMMX Comparison

Compare BRSP & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrightSpire Capital Inc.

BRSP

BrightSpire Capital Inc.

HOLD

Current Price

$5.35

Market Cap

738.7M

Sector

Real Estate

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$9.42

Market Cap

716.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRSP
IMMX
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
738.7M
716.2M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
BRSP
IMMX
Price
$5.35
$9.42
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.50
$19.20
AVG Volume (30 Days)
2.2M
2.3M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
11.03%
N/A
EPS Growth
75.24
N/A
EPS
0.03
N/A
Revenue
$330,587,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.54
N/A
P/E Ratio
$177.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$1.94
52 Week High
$6.17
$12.14

Technical Indicators

Market Signals
Indicator
BRSP
IMMX
Relative Strength Index (RSI) 43.09 46.03
Support Level $5.24 $7.99
Resistance Level $5.46 $10.61
Average True Range (ATR) 0.11 0.93
MACD 0.01 -0.21
Stochastic Oscillator 38.96 23.05

Price Performance

Historical Comparison
BRSP
IMMX

About BRSP BrightSpire Capital Inc.

BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: